Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases...
3 insider purchases on record · latest filing 2026-01-05.
Insiders have also filed 9 sale transactions at CLYM.